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ABSTRACT
Background
A gap exists between evidence and practice regarding the management of cardiovascular
risk factors. This gap could be narrowed if systematically developed clinical practice guidelines
were effectively implemented in clinical practice. We evaluated the effects of a tailored
intervention to support the implementation of systematically developed guidelines for the use
of antihypertensive and cholesterol-lowering drugs for the primary prevention of cardiovas-
cular disease.
Methods and Findings
We conducted a cluster-randomized trial comparing a tailored intervention to passive
dissemination of guidelines in 146 general practices in two geographical areas in Norway. Each
practice was randomized to either the tailored intervention (70 practices; 257 physicians) or
control group (69 practices; 244 physicians). Patients started on medication for hypertension or
hypercholesterolemia during the study period and all patients already on treatment that
consulted their physician during the trial were included. A multifaceted intervention was
tailored to address identified barriers to change. Key components were an educational
outreach visit with audit and feedback, and computerized reminders linked to the medical
record system. Pharmacists conducted the visits. Outcomes were measured for all eligible
patients seen in the participating practices during 1 y before and after the intervention. The
main outcomes were the proportions of (1) first-time prescriptions for hypertension where
thiazides were prescribed, (2) patients assessed for cardiovascular risk before prescribing
antihypertensive or cholesterol-lowering drugs, and (3) patients treated for hypertension or
hypercholesterolemia for 3 mo or more who had achieved recommended treatment goals.
The intervention led to an increase in adherence to guideline recommendations on choice of
antihypertensive drug. Thiazides were prescribed to 17% of patients in the intervention group
versus 11% in the control group (relative risk 1.94; 95% confidence interval 1.49–2.49, adjusted
for baseline differences and clustering effect). Little or no differences were found for risk
assessment prior to prescribing and for achievement of treatment goals.
Conclusions
Our tailored intervention had a significant impact on prescribing of antihypertensive drugs,
but was ineffective in improving the quality of other aspects of managing hypertension and
hypercholesterolemia in primary care.
The Editors’ Summary of this article follows the references.
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Hypertension and hypercholesterolemia are common
problems in general practice and have important consequen-
ces for patients and the use of health-care resources.
There is high-quality evidence from well-designed random-
ized trials of the effects of antihypertensive and cholesterol-
lowering drugs for the primary prevention of cardiovascular
disease [1,2]. However, a gap exists between evidence and
practice regarding several aspects of cardiovascular risk
factor management [3]. This gap could be narrowed if
systematically developed clinical practice guidelines were
effectively implemented. Several randomized trials of guide-
line implementation strategies have been conducted, gener-
ally demonstrating only modest effects [4].
Based on a review of previous guidelines and the under-
lying evidence, we developed guidelines for prescribing
antihypertensive and cholesterol-lowering drugs for the
primary prevention of cardiovascular disease in Norwegian
general practice [5–7].
We decided to address possible improvements for three key
issues: cardiovascular risk is commonly not estimated before
starting treatment [8], thiazides are underutilized when initiat-
ing treatment for hypertension [9], and treatment goals are
frequently not achieved for both blood pressure and choles-
terol [10,11]. We therefore developed an intervention aimed at
improving performance in these three areas and conducted a
trial to assess the effectiveness and costs of this intervention.
The results of evaluations of interventions to improve
clinical practice differ, and large effects are not common
[12,13]. As with any behavior, professional behavior is difﬁcult
to change. The underlying reasons for differences between
clinical practice and recommendations in systematically
developed guidelines vary from one clinical problem to
another and from one clinician to another [14,15]. It is
therefore logical to attempt to tailor strategies to support the
implementation of guidelines to address identiﬁed barriers to
change [15]. However, the effectiveness of tailored interven-
tions is uncertain [16].
The primary objective of this trial was to evaluate the
effects of a tailored intervention to support the implementa-
tion of guidelines in Norwegian general practice for the use
of antihypertensive and cholesterol-lowering drugs for the
primary prevention of cardiovascular disease. Our hypothesis
was that the tailored intervention would be more effective
than passive dissemination of the guidelines.
Methods
We anticipated that passive dissemination of guidelines
would have little effect on the outcomes of interest [12,13,18]
and therefore was an appropriate control intervention. We
decided that randomizing practices rather than physicians or
patients would be the most feasible design for practical
reasons, and also the most appropriate to avoid contami-
nation from the intervention to the control group.
The methods have been described in more detail in the
study protocol (Protocol S1; [18]).
Participants
The study participants were all general practices in two
geographically deﬁned areas of Norway; the practices all used
one or the other of two eligible electronic medical record
systems.
Patients started on medication for hypertension or hyper-
cholesterolemia during the study period and all patients
already on treatment that consulted their physician during
the trial were included in the analyses. The eligibility criteria
for patients are described in more detail under ‘‘Outcomes.’’
Interventions
We developed our intervention through a process of
identifying barriers to implementation of the recommenda-
tions and tailoring the intervention to address these. This is
described in more detail elsewhere [19]. Box 1 shows the
various elements of our intervention.
The intervention was initiated through an educational
outreach visit carried out between May and December 2002
by pharmacists recruited and trained speciﬁcally for this
purpose.
During the outreach visit the main elements of the
guidelines were presented, with special emphasis on cardio-
vascular risk estimation, choice of ﬁrst-line drugs for hyper-
tension, and treatment goals. A printed copy of the guidelines
and a one-page version were given to the physicians,
including a chart to aid the estimation of cardiovascular risk.
A software package was installed during the visit. This
Box 1. Components of the Tailored Intervention
Educational Outreach Visit
 Presentation focusing on three main messages: (1) relevance of risk
estimation and how to do it, including strategies on how to
communicate information about risk to patients, (2) evidence of the
effectiveness of thiazides and that fears of adverse effects are
unjustified, and pointing out the consensus that exists among
guidelines (attention also directed to the importance of clinically
relevant endpoints when studies are quoted), and (3) clear
recommendations justified by referring to the high degree of
consensus among guidelines
 Guidelines handed out, directing attention to the authors (opinion
leaders)
Audit and Feedback at Outreach Visit
 To what extent treatment goals are currently being achieved
 Drug choice profile on antihypertensives
 Level of risk among patients on treatment, compared to a sample
(men, 40–65 y) not on treatment
Computerized Reminders
 Risk assessment
 First-choice antihypertensive drugs
 Treatment goals
Risk Assessment Tools (Software and Charts)
Patient Information Material
 The relationship between single risk factors and global risk
 Thiazides and beta-blockers.
 Treatment goals
Follow-Up
 Telephone call within 1–3 d to check that software had not led to
any difficulties
 Short telephone interview with each physician after 1–3 mo
PLoS Medicine | www.plosmedicine.org June 2006 | Volume 3 | Issue 6 | e134 0784
RaPP Trial: Principal Findingsenabled us to extract data and immediately, during the visit,
present the physicians with data on their performance of risk
estimation, choice of antihypertensive drugs, and achieve-
ment of treatment goals (audit and feedback). The software
package also included computerized reminders (‘‘pop-ups’’)
on the computer screen. These were triggered at the patient’s
ﬁrst visit following a recording of an elevated blood pressure
(.140/90 mm Hg) or cholesterol level (total cholesterol . 5
mmol/l [190 mg/dl] or low-density lipoprotein [LDL] choles-
terol . 3 mmol/l [115 mg/dl]).
If the patient had not been prescribed blood-pressure- or
cholesterol-lowering drugs, the physician was reminded of
the recommendation to carry out cardiovascular risk assess-
ment and was given the option of starting a computer
program for risk assessment. Recommendations on choice of
drugs were also given, and the physician was given the choice
of printing out patient information material.
If the patient was already on blood-pressure- or cholester-
ol-lowering drugs, the pop-up reminded the physician of
recommended treatment goals and asked if the physician
would like to print out patient information material.
Within 3 d after the outreach visit, a member of the
research team called the clinic to conﬁrm that they were not
experiencing problems with their computers as a result of our
visit.
The doctors who were invited to participate in the study
were given information about the objectives of the study and
the practical impact it might have on their practice. We
obtained written consent from all practices. We submitted
the research protocol to the Regional Committee of Research
Ethics, which considered ethical approval unnecessary.
The Norwegian Data Inspectorate approved the handling
of the data.
Outcomes
We chose three main outcome measures, all aimed at
physician behavior regarding the pharmacological manage-
ment of primary prevention of cardiovascular disease for the
12 mo following the outreach visit. All outcomes were
recorded at the patient level. Because the eligibility criteria
varied from one outcome to another, the number of patients
included in the analysis varied across outcomes. Baseline
data for the 12 mo preceding the intervention were also
collected.
Patients with established cardiovascular disease were
excluded, with the exception of the outcomes related to
treatment goals for lipid-lowering therapy, since these are the
same across patient groups. Because antihypertensive drugs
are also prescribed for the treatment of thyrotoxicosis and
migraine, we excluded data from patients with these
diagnoses. We used extracted medical record data on
prescribing and diagnoses to identify patients who were to
be excluded. For example, patients who had been given a
prescription for nitroglycerin were assumed to have coronary
heart disease, and thus were excluded from most analyses.
Patients were considered to be previously untreated if they
had hypertension (blood pressure . 140/90 mm Hg) or
hypercholesterolemia (total cholesterol . 5 mmol/l [190 mg/
dl] or LDL cholesterol . 3 mmol/l [115 mg/dl]) but no
prescription for the corresponding medication had been
recorded for 24 mo preceding the outreach visit.
The primary outcomes were the following: (1) the propor-
tion of patients prescribed thiazides among patients pre-
Figure 1. Flow of Practices through Trial
aFor two of these practices no outreach visit was conducted (one withdrew after randomization and one had technical problems) but data collection
was possible.
DOI: 10.1371/journal.pmed.0030134.g001
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proportion of patients with a cardiovascular risk assessment
among all those started on antihypertensive or cholesterol-
lowering treatment (excluding patients already on either type
of medication), and (3) the proportion of patients with a
recorded level of cholesterol (total or LDL) or blood pressure
satisfying the speciﬁed treatment goals among all patients on
the corresponding treatment for at least 3 mo. For
cholesterol we also included patients on secondary preven-
tion since the treatment goals are similar.
The secondary outcomes, as prespeciﬁed in the research
protocol (Protocol S1; [18]), were the following: (1) the
proportion of patients reporting that they were involved in
the decision-making process before drug treatment for
hypertension and/or elevated cholesterol was started, (2)
the level of risk among patients started on treatment, (3) the
proportion of patients with risk above 20% among those
started on treatment, (4) the level of risk among patients not
started on treatment for whom blood pressure and
cholesterol level were recorded, (5) the proportion of
prescriptions of thiazides or beta-blockers to patients who
were prescribed antihypertensive drugs for the ﬁrst time, (6)
the proportion of prescriptions of angiotensin receptor
blockers or alpha-blockers to patients who were prescribed
antihypertensive drugs for the ﬁrst time, (7) for patients with
diabetes, the proportion of patients with a recorded level of
cholesterol (total or LDL) or hypertension satisfying the
speciﬁed treatment goals among all patients on the
corresponding treatment (for cholesterol we also included
patients on secondary prevention since the treatment goals
are similar), (8) the proportion of patients reaching the
speciﬁed treatment goal for blood pressure, and (9) the
proportion of patients reaching the speciﬁed treatment goal
for cholesterol level.
All outcomes were calculated from data extracted from the
practices’ medical record systems, with two exceptions: (1) the
use of cardiovascular risk assessment tools by physicians
before starting medication and (2) the level of patient
involvement. Patients potentially eligible for inclusion in
these analyses were identiﬁed from the medical record data,
after which we interviewed the prescribing physician (or a
colleague) per telephone. We enquired about the use of risk
assessment tools for each patient they had started on
treatment during the intervention period, and the physicians
gave their answers based on notes from the medical records.
The physicians assisted us by sending a questionnaire to the
patients who had been started on medication. The question-
naire consisted of one question, asking to what extent the
patients felt that they had taken part in the decision to start
drug therapy. The answer was given on a ﬁve-point scale,
from ‘‘none’’ to ‘‘fully.’’ Only patients reporting that they
took no part at all were counted as not being involved in the
decision to start treatment.
For two outcomes—(1) the proportion of patients for
whom cardiovascular risk had not been estimated and (2) the
level of risk among patients not started on treatment—the
analysis was based on a random sample of eligible patients.
During interviews with physicians it was often possible to
ﬁgure out whether a practice was in the intervention group.
Investigators assessing outcomes and conducting analyses
were blinded to the allocation of practices.
All analyses were by intention to treat. In response to
comments from peer reviewers, we decided to deviate from
our protocol and use adherence, rather than non-adherence,
to recommendations as outcome measures. This had no
impact on our ﬁndings.
Sample Size
In order to demonstrate a 25% relative reduction in non-
adherence with the guidelines—with a power of 80% and a
statistical signiﬁcance level of 5%—in outcome measures
between the control and intervention groups, we estimated
that we needed a sample of approximately 140 practices in
total (Cluster Randomisation Sample Size Calculator version
1.0.2, Health Services Research Unit, University of Aberdeen,
Aberdeen, United Kingdom). The adjusting factor (intra-
cluster correlation coefﬁcient) was conservatively estimated
to be 0.2, based on data from a previous study [20]. More
detail is available elsewhere [18].
Randomization
Block randomization was done within two geographical
areas (Oslo and Tromsø) to ensure balance in the number of
practices in the intervention and control groups. The size of
the blocks varied randomly between two, four, and six. A
colleague not directly involved in our research project
generated the allocation list using software from http://www.
randomization.com. We gave her identiﬁcation numbers
representing each recruited practice, and she informed us
whether the practice was allocated to the intervention or
control group.
Table 1. Baseline Characteristics
Type of Factor Factors at Baseline Intervention Group Control Group
Practice Number of practices 73 73
Number of practices in Oslo area 63 62
Number of practices in Tromsø area 10 11
Mean number of physicians per practice (SD)
a 2.7 (1.6) 3.0 (1.6)
Patient Mean age (SD)
b 61.2 (13.5) 60.5 (13.5)
Number (percent) male
b 1,519/3,316 (45.8) 1,382/2,863 (48.3)
aData missing from three practices: two in the intervention group and one in the control group.
bAmong patients started on medication for uncomplicated hypertension or hypercholesterolemia in the previous year.
SD, standard deviation.
DOI: 10.1371/journal.pmed.0030134.t001
PLoS Medicine | www.plosmedicine.org June 2006 | Volume 3 | Issue 6 | e134 0786
RaPP Trial: Principal FindingsStatistical Methods
The generalized estimating equations (GEE) approach was
used for the analysis of the binary outcomes, and the mixed
effects linear regression model (a two-stage nested analysis of
variance) for the continuous outcome (risk level), using the
baseline log odds for compliance and the baseline mean risk
level for each practice, respectively, as covariates [21]. The
analysis was performed using PROC GENMOD and PROC
MIXED in SAS 9.1.3 (SAS Institute, Cary, North Carolina,
United States).
The outcome from a GEE approach is an odds ratio; the
adjusted relative risk was calculated from the odds ratio by
using the overall proportion of compliance in the control
group [22].
Originally we planned to use a parametric method, which
depends on an underlying distribution of the sample
observations. This is not the case for the GEE approach. We
therefore used the GEE approach rather than the method we
had speciﬁed in the protocol. This change was made before
we analyzed the data.
Results
Participant Flow
Figure 1 illustrates the ﬂow of practices (clusters) through
the trial. Out of the 388 practices that were invited, 146
agreed to participate. One practice withdrew after random-
ization, before the outreach visit. The practices and patients
in the intervention and control groups were similar with
regards to baseline characteristics (Table 1).
Data Collection
For seven of the 146 participating practices we were unable
to collect medical record data for various reasons (Figure 1).
One of the remaining 139 practices was not included in the
analyses involving estimation of cardiovascular risk (three
secondary outcomes) because of an error during data
collection. The numbers of patients included in the analyses
are shown in Figure 2.
We interviewed 339 physicians about their use of risk
assessment tools. For another 108 physicians, information was
Figure 2. Patient Populations in Analyses
aQuestionnaires were not sent to some patients included in the analysis of risk assessment (patient had died, unknown address, etc.), and some patients
were excluded from the analysis of risk assessment after questionnaires had been sent to them.
DOI: 10.1371/journal.pmed.0030134.g002
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89% of all physicians.
For the questionnaire, which was sent to 1,620 patients, we
achieved a response rate of 59%.
Primary Outcomes
The main ﬁndings are presented in Table 2. Thiazide
prescribing increased from 5.8% to 17.3% in the experi-
mental group, and from 8.8% to 11.1% in the control group.
Thus, prescribing of thiazides was signiﬁcantly higher in the
experimental group (relative risk 1.94; 95% conﬁdence
interval [CI]1.49–2.49). Little or no effect was detected for
the two other main outcomes.
Secondary Outcomes
The results for the secondary outcomes are reported in
Table 3. There were no statistically signiﬁcant differences for
these outcomes, except for those related to choice of
antihypertensive drug. The distribution of responses to the
patient questionnaire was similar in the two groups.
Discussion
The intervention had an impact on prescribing patterns,
but for other outcomes no statistically signiﬁcant effects
were found.
Strengths and Weaknesses of the Study
Compared to other evaluations of quality improvement
interventions, the size of the study and use of rigorous
scientiﬁc methods are the main strengths of our study.
The risk of selection bias was minimized by the
randomized design. The impact of random errors was
minimized by including 146 practices with 500 physicians
and a large number of patients (between 950 and 33,800
per outcome).
Several assumptions had to be made during data analysis,
such as assuming that patients were not on medication if no
prior prescription for antihypertensive therapy was recorded.
Some of the patients proved to be on medication that had
been prescribed elsewhere. Similarly, we relied on routinely
collected clinical data for coding patients as smokers or
nonsmokers, and these data may be incomplete even though
we searched the free-text notes area of the medical records
for information on smoking. However, we can assume that
these errors are evenly distributed between the intervention
and control groups, and thus should not introduce biases into
the analyses.
One outcome was based on self-report by physicians, and
another on self-report by patients. It is possible that
physicians in the experimental group tended to report a
higher use of risk assessment tools since this had been
promoted to them. However, the reported use of risk
assessment tools was similar in the two groups.
Practices in only two areas of Norway were invited to
participate in the trial, and only 38% of them were included.
Some practices were not invited because they did not use a
medical record system compatible with our software. Thus,
the practices in the trial are not necessarily representative for
all general practices in Norway. Compared to national
statistics, the proportion of practices with only one or two
physicians was higher in our study (48% versus a national
average of 30%).
Study Findings in Relation to the Overall Evidence
Walsh and colleagues recently conducted a systematic
review of studies evaluating quality improvement interven-
tions for the management of hypertension [23]. They
included four randomized controlled trials of interventions
targeting the choice of antihypertensive drug [24–27]. None
of these trials reported statistically signiﬁcant results. The
point estimates for effect sizes ranged from2.6% to 6%. The
corresponding ﬁgure for our study is 9.3%. The review also
included some nonrandomized studies, and the authors’
overall conclusion was that ‘‘the median increase in percent-
age of providers adhering to recommendations was 3.0%’’
(interquartile range 1.0%–5.5%).
One randomized trial published too recently to be included
in the systematic review was also aimed at increasing the
prescribing of thiazides [28]. The intervention involved case-
based educational modules and personal prescribing feed-
back. The investigators reported an absolute effect size
slightly better than ours: an increase in thiazide prescribing
of 11.5% (95% CI 4.0%–18.8%). Thus, although the results
from trials targeting professional behavior have often been
Table 2. Primary Outcomes
Outcome Intervention Group Control Group Percentage
Difference
Intracluster
Correlation
Coefficient
Relative
Risk
a
(95% CI)
p-Value
a
Baseline
Period
Follow-Up
Period
Percentage
Change
Baseline
Period
Follow-Up
Period
Percentage
Change
Prescribing of thiazides
for hypertension
b
161/2,784
(5.8%)
378/2,184
(17.3%)
11.5 209/2,365
(8.8%)
218/1,968
(11.1%)
2.2 9.3 0.087 1.94 (1.49; 2.49) ,0.001
Cardiovascular risk
assessment done
— 147/854
(17.2%)
— — 112/768
(14.6%)
— 2.6 0.39 1.04 (0.60; 1.71) 0.90
Treatment goal
achieved
c
4,669/15,914
(29.3%)
5,502/17,213
(32.0%)
2.6 5,174/15,411
(33.6%)
6,056/16,593
(36.5%)
2.9 0.3 0.026 0.98 (0.93; 1.02) 0.33
aAdjusted for baseline differences and clustering effects (GEE).
bFewer data on exclusion criteria were available for the baseline period, explaining the higher number of prescriptions than during follow-up.
cRecommended treatment goal for blood pressure is less than 140/90 mm Hg; for lipids is total cholesterol , 5 mmol/l (190 mg/dl) and/or LDL cholesterol , 3 mmol/l (115 mg/dl).
DOI: 10.1371/journal.pmed.0030134.t002
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ing those reported by us.
Walsh et al. also reviewed trials of interventions aimed at
improving the achievement of treatment goals for patients on
antihypertensive therapy. They found a median increase in
the proportion of patients achieving recommended targets of
systolic and diastolic blood pressure of 16.2% (interquartile
range 10.3%–32.2%) and 6.0% (interquartile range 1.5%–
17.5%), respectively. Nonrandomized trials were also in-
cluded in this analysis. The greatest effect sizes were achieved
with interventions involving organizational change and
patient education. Our intervention included no such
components, apart from giving physicians the ability to print
out patient education materials incorporated into their
medical record system.
Possible Explanations
Some speciﬁc areas of professional behavior may be more
difﬁcult to inﬂuence than others. For instance, physicians are
under immense pressure from the pharmaceutical industry to
choose antihypertensive drugs other than thiazides, which are
off-patent drugs available at a low price. On the other hand,
achieving treatment goals and conducting cardiovascular risk
assessment are uncontroversial recommendations that are
encouraged by practically all stakeholders. Attitudes and lack
of knowledge among physicians are likely to be the main
barriers to adhering to these recommendations, and our
intervention was speciﬁcally designed to address these [19].
Despite our targeted intervention, we did not succeed in
having an impact on these behaviors. One explanation may
be that achieving treatment goals is a patient outcome, which
depends on compliance of patients as well as physicians. Our
intervention was mainly directed at physician behavior. We
have no good explanation for the lack of effect on the use of
risk assessment tools. A process evaluation is underway, to
identify why the intervention did not have an effect on
various outcomes across practices.
The outreach visits were conducted as group sessions with
all the physicians in the practice. It is likely that visiting
physicians individually is more effective [29], but this is also
more costly to implement. Our intervention was multi-
faceted, and it is not possible to say which of the various
components were the most important for the overall
effectiveness. The planned process evaluation may provide
some insight.
Although we managed to nearly double the prescribing of
thiazides, it can be argued that the effect is far from
satisfactory. The use of thiazides is still very limited in
Norway, and although we achieved a rate of 17% for the
prescribing of thiazides, this is low relative to other countries
and relative to what might be considered appropriate [30].
An alternative strategy for quality improvement is the use
Table 3. Secondary Outcomes
Outcome Intervention Group Control Group Percentage
Difference
Intracluster
Correlation
Coefficient
Relative
Risk
a
(95% CI)
p-Value
a
Baseline
Period
Follow-Up
Period
Percentage
Change
Baseline
Period
Follow-Up
Period
Percentage
Change
Patients involved in
decision-making
— 454/508
(89.4%)
— — 382/442
(86.4%)
— 2.9 0 1.03
(0.98; 1.07)
0.16
Cardiovascular risk
among patients started
on treatment (SD)
15.1%
(8.6%)
14.3%
(8.5%)
0.8 14.5%
(8.6%)
14.0%
(8.6%)
0.5 0.3 0.035 — 0.90
Patients with
cardiovascular
risk above 20%
584/2,264
(25.8%)
433/1,889
(22.9%)
2.9 472/2,017
(23.4%)
359/1,629
(22.0%)
1.4 1.5 0.014 0.99
(0.85; 1.14)
0.91
Cardiovascular risk
among patients not
started on treatment (SD)
— 8.0%
(6.8%)
— — 7.6%
(6.6%)
— 0.4 0.050 — 0.92
Prescribing of
thiazides and
beta-blockers
b
816/2,784
(29.3%)
889/2,184
(40.7%)
11.4 744/2,365
(31.5%)
632/1,968
(32.1%)
0.7 10.8 0.073 1.41
(1.27; 1.56)
,0.001
Prescribing of
angiotensin II
receptor blockers
and alpha-blockers
b
1,252/2,784
(45.0%)
876/2,184
(40.1%)
4.9 1,099/2,365
(46.5%)
945/1,968
(48.0%)
1.6 3.3 0.084 1.21
(1.10; 1.30)
,0.001
Treatment goal
achieved among
diabetes patients
c
733/2,397
(30.6%)
905/2,875
(31.5%)
0.9 759/2,482
(30.6%)
994/2,950
(33.7%)
3.1 2.2 0.028 0.96
(0.87; 1.06)
0.46
Treatment goal for
hypertension achieved
c
2,635/10,620
(24.8%)
3,073/11,308
(27.2%)
2.4 2,980/10,031
(29.7%)
3,310/10,564
(31.3%)
1.6 0.8 0.032 1.00
(0.95; 1.06)
0.89
Treatment goal for
cholesterol achieved
c
2,925/6,945
(42.1%)
3,545/7,815
(45.4%)
3.2 3,068/6,854
(44.8%)
3,770/7,711
(48.9%)
4.1 0.9 0.040 0.97
(0.91; 1.02)
0.23
aAdjusted for baseline differences and clustering effects (GEE).
bFewer data on exclusion criteria were available for the baseline period, explaining the higher number of prescriptions than during follow-up.
cRecommended treatment goal for blood pressure is less than 140/90 mmHg; for lipids is total cholesterol , 5 mmol/l (190 mg/dl) and/or LDL cholesterol , 3 mmol/l (115 mg/dl).
SD, standard deviation.
DOI: 10.1371/journal.pmed.0030134.t003
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Legislation went into effect in March 2004 that requires
Norwegian doctors to prescribe thiazides as the ﬁrst-choice
antihypertensive drug if the patients are to have their drug
costs reimbursed through the national health insurance
system. However, the effect of such legislative measures is
not well documented. Our results are in line with those of
other randomized trials that have found outreach visits to be
effective at changing prescribing, with similar effect sizes
(median adjusted risk difference 3%, range 0%–7.5%, for 12
studies), while effects on other outcomes are much less
consistent [31]. We did not ﬁnd our intervention to be
effective for other behaviors. We report on the cost
effectiveness of our intervention in a companion article [32].
Supporting Information
Trial Registration. This trial has the registration number
ISRCTN48751230 in the International Standard Randomized Con-
trolled Trial Number Register.
Found at: http://www.controlled-trials.com/isrctn/trial/|/0/48751230.
html.
Protocol S1. Trial Protocol
Found at DOI: 10.1371/journal.pmed.0030134.sd001 (310 KB PDF).
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RaPP Trial: Principal FindingsEditors’ Summary
Background. An important issue in health care is ‘‘getting research into
practice,’’ in other words, making sure that, when evidence from
research has established the best way to treat a disease, doctors actually
use that approach with their patients. In reality, there is often a gap
between evidence and practice.
An example concerns the treatment of people who have high blood
pressure (hypertension) and/or high cholesterol. These are common
conditions, and both increase the risk of having a heart attack or a stroke.
Research has shown that the risks can be lowered if patients with these
conditions are given drugs that lower blood pressure (antihypertensives)
and drugs that lower cholesterol. There are many types of these drugs
now available. In many countries, the health authorities want family
doctors (general practitioners) to make better use of these drugs. They
want doctors to prescribe them to everyone who would benefit, using
the type of drugs found to be most effective. When there is a choice of
drugs that are equally effective, they want doctors to use the cheapest
type. (In the case of antihypertensives, an older type, known as thiazides,
is very effective and also very cheap, but many doctors prefer to give
their patients newer, more expensive alternatives.) Health authorities
have issued guidelines to doctors that address these issues. However, it
is not easy to change prescribing practices, and research in several
countries has shown that issuing guidelines has only limited effects.
Why Was This Study Done? The researchers wanted—in two parts of
Norway—to compare the effects on prescribing practices of what they
called the ‘‘passive dissemination of guidelines’’ with a more active
approach, where the use of the guidelines was strongly promoted and
encouraged.
What Did the Researchers Do and Find? They worked with 146 general
practices. In half of them the guidelines were actively promoted. The
remaining were regarded as a control group; they were given the
guidelines but no special efforts were made to encourage their use. It
was decided at random which practices would be in which group; this
approach is called a randomized controlled trial. The methods used to
actively promote use of the guidelines included personal visits to the
practices by pharmacists and use of a computerized reminder system.
Information was then collected on the number of patients who, when
first treated for hypertension, were prescribed a thiazide. Other
information collected included whether patients had been properly
assessed for their level of risk (for strokes and heart attacks) before
antihypertensive or cholesterol-lowering drugs were given. In addition,
the researchers recorded whether the recommended targets for
improvement in blood pressure and cholesterol level had been reached.
Only 11% of those patients visiting the control group of practices who
should have been prescribed thiazides, according to the guidelines,
actually received them. Of those seen by doctors in the practices where
the guidelines were actively promoted, 17% received thiazides.
According to statistical analysis, the increase achieved by active
promotion is significant. Little or no differences were found for risk
assessment prior to prescribing and for achievement of treatment goals.
What Do These Findings Mean? Even in the active promotion group,
the great majority of patients (83%) were still not receiving treatment
according to the guidelines. However, active promotion of guidelines is
more effective than simply issuing the guidelines by themselves. The
study also demonstrates that it is very hard to change prescribing
practices. The efforts made here to encourage the doctors to change
were considerable, and although the results were significant, they were
still disappointing. Also disappointing is the fact that achievement of
treatment goals was no better in the active-promotion group. These
issues are discussed further in a Perspective about this study (DOI: 10.
1371/journal.pmed.0030229).
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030134.
 The Web site of the American Academy of Family Physicians has a
page on heart disease
 The MedlinePlus Medical Encyclopedia’s pages on heart diseases and
vascular diseases
 Information from NHS Direct (UK National Health Service) about heart
attack and stroke
 Another PLoS Medicine article has also addressed trends in thiazide
prescribing
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